Rosiglitazone, PPARγ, and type 2 diabetes

New England Journal of Medicine

Volumn 363, Issue 27, 2010, Pages 2667-2669

  Kahn, Barbara B ^a   McGraw, Timothy E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ROSIGLITAZONE;

ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; FLUID RETENTION; FRACTURE; GENE EXPRESSION; HUMAN; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; WEIGHT GAIN;

EID: 78650885151     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1012075     Document Type: Article

References (6)

1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29.
2. Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010;466:451-456.
3. Schopfer FJ, Cole MP, Groeger AL, et al. Covalent peroxisome proliferator-activated receptor ? adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem 2010;285:12321-33.
4. McGuire DK, Inzucchi S. New drugs for the treatment of diabetes mellitus. I. Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117:440-449.
5. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-139.
6. DeSouza C, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov 2009;8:361-367.